Kite Pharma

Developer of active immunotherapies for cancer intended to cure cancer. The company is engaged in developing engineered cell therapies that express either a chimeric antigen receptor (CAR) or a T cell receptor (TCR), depending on the type of cancer. It's dual platform has the potential to change the paradigm of cancer therapy and address both hematological and solid tumor cancers.

View Website